- Keymed Biosciences of Chengdu completed a $378.5 million Hong Kong IPO to develop its portfolio of antibody candidate.
- I-Mab announced two partnerships to develop oncology candidates with China biopharmas that offer novel discovery technologies.
- Eucure Biopharma has been approved to start US Phase II trials of two antibodies.
- China is planning to regulate domestic technology companies that want to list on foreign exchanges.
- Foreign IPOs did not previously require China's approval, but now they will.
For further details see:
Week In Review: Keymed Completes $378 Million IPO In Hong Kong For Antibody Drugs